View Cart  

EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs

A A
Drugmakers evaluating multiple sclerosis (MS) treatments for the EU should use relapse rate as the primary efficacy parameter in clinical trials for relapsing-remitting MS or secondary progressive MS with superimposed relapses, according to a draft EMA guideline.

To View This Article:

Login

Subscribe To Drug Industry Daily